Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.65 |
| ▸ | SRC | P12931 | 12/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498795 | 0.86 | SRC (0.63) | MAP2K1SRCEGFRERBB2ABL1 | |
| SCHEMBL7071162 | 0.86 | SRC (0.59) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL5723486 | 0.86 | SRC (0.56) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4495250 | 0.83 | SRC (0.60) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4498460 | 0.83 | SRC (0.66) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4487269 | 0.83 | SRC (0.53) | MAP2K1SRCEGFRERBB2ABL1 | |
| SCHEMBL4496968 | 0.82 | MAP2K1 (0.59) | MAP2K1SRCEGFRERBB2ABL1 | |
| SCHEMBL5452058 | 0.81 | SRC (0.55) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4487359 | 0.81 | SRC (0.57) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4487506 | 0.81 | SRC (0.60) | SRCEGFRERBB2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |